ScreenerHero

LENZ LENZ Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · lenz-tx.com
3.620USD-4.49%Mkt Cap: 113.74M $P/E: —

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and L…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap113.74M USD
Enterprise Value-100.35M USD
Revenue (TTM)21.48M USD
Gross Profit18.67M USD
Net Income (TTM)-82.13M USD
Revenue/Share0.70 USD
Last Price3.620 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees152
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.23
PEG—
EV/EBITDA0.74
EV/Revenue-4.67
P/S5.55
P/B0.54
EPS (TTM)-4.36
EPS (Forward)-3.08
52W Range
3.4550% of range50.40
52W High50.40 USD
52W Low3.455 USD
Profitability
Gross Margin97.81%
Oper. Margin-622.89%
EBITDA Margin0.00%
Profit Margin-430.25%
ROE-28.88%
ROA-26.85%
Growth
Revenue Growth9.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-69.17M USD
CapEx (TTM)827.00K USD
FCF Margin-331.79%
FCF Yield-62.64%
Net Debt-219.43M USD
Net Debt/EBITDA1.62
Balance Sheet
Debt/Equity0.00
Current Ratio13.55
Quick Ratio12.91
Book Value/Sh6.98 USD
Cash/Share7.00 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay DateMar 21, 2024
Splits
Last Split1:7
Split DateMar 22, 2024
Analyst Consensus
Rating—
Target (Mean)24.00 USD
Upside (mean)+563.0%
Target Range7.000 USD – 60.00 USD
7.000+563.0% to mean60.00
# Analysts7
Ownership
Shares Out.31.42M
Float18.39M
Insiders2.65%
Institutions111.76%
Short Interest
Short Ratio16.2d
Short % Float55.65%
Short % Out.33.83%
Shares Short10.63M
Short (prev mo.)11.20M
Technical
SMA 504.755 (-23.9%)
SMA 2009.275 (-61.0%)
Beta1.73
S&P 52W Chg16.45%
Avg Vol (30d)718.55K
Avg Vol (10d)798.89K
Technical Indicators
RSI (14)34.4
MACD-0.3636
MACD Signal-0.3564
MACD Hist.-0.0072
BB Upper5.043 USD
BB Middle4.094 USD
BB Lower3.145 USD
BB Width46.35%
ATR (14)0.2748 USD
Vol Ratio (20d)0.67x